Indoco Remedies board meeting scheduled for May 7, 2026 to approve audited standalone and consolidated financial results for Q4 and FY ending March 31, 2026.
Board will consider recommending a final dividend for FY 2025-26, subject to their decision during the meeting.
Trading window closure for designated persons extended until May 9, 2026, maintaining compliance with SEBI regulations.